CLEAR GUIDANCE ON PRACTICAL CONSIDERATIONS WITH LIXIANA®
Increasing renal function in NVAF
A trend towards decreasing efficacy with increasing creatinine clearance was observed for LIXIANA® compared to well-managed warfarin. Therefore, LIXIANA® should only be used in patients with NVAF and high creatinine clearance after a careful evaluation of the individual thromboembolic and bleeding risk.
Assessment of renal function:
CrCl should be monitored at the beginning of the treatment in all patients and afterwards when clinically indicated.